Abstract
Purpose
The sphingosine-1-phosphate receptor 1 (S1PR1) is an important biomarker for imaging inflammation in the central nervous system (CNS). Herein, we report our recent evaluation of four 18F-labeled S1PR1 tracers (18F-TZ43113, 18F-TZ35104, 18F-TZ4877, and 18F-TZ4881) in a rat model of multiple sclerosis (MS).
Procedures
MicroPET studies of each tracer’s uptake and kinetics were performed in an experimental autoimmune encephalomyelitis (EAE) rat model of MS to quantify upregulated S1PR1 expression in the lumbar spinal cord of EAE rats. Western blot analysis was conducted to confirm the differences in the expression of S1PR1 protein level between EAE and sham rats. Radiometabolite analysis was performed for the most promising candidate in rats.
Results
All four S1PR1 tracers detected increased S1PR1 levels in response to neuroinflammation in the lumbar spinal cord of EAE rats, which was supported by western blot results. The ranked order of tracer uptake in rat spinal cord was 18F-TZ4877 > 18F-TZ4881 > 18F-TZ35104 > 18F-TZ43113. 18F-TZ4877 had the highest uptake of the four tracers and showed good kinetic modeling fits in rat spinal cord using an image-based method of arterial blood input function. Radiometabolite analysis of 18F-TZ4877 showed good in vivo stability with no major radiometabolite accumulation in the rat brain.
Conclusion
Among these four new PET tracers, 18F-TZ4877 showed the most favorable profile for assessing S1PR1 expression in the EAE rat model of MS. Further characterization of these radiotracers in other models of neuroinflammation is warranted to identify a promising 18F-labeled tracer for imaging S1PR1 in vivo.
Similar content being viewed by others
References
Proia RL, Hla T (2015) Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy. J Clin Invest 125:1379–1387
Blaho VA, Hla T (2014) An update on the biology of sphingosine 1-phosphate receptors. J Lipid Res 55:1596–1608
Lee MJ, Van Brocklyn JR, Thangada S et al (1998) Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. Science 279:1552–1555
Karuppuchamy T, Behrens EH, Gonzalez-Cabrera P et al (2017) Sphingosine-1-phosphate receptor-1 (S1P1) is expressed by lymphocytes, dendritic cells, and endothelium and modulated during inflammatory bowel disease. Mucosal Immunol 10:162–171
Maceyka M, Spiegel S (2014) Sphingolipid metabolites in inflammatory disease. Nature 510:58–67
Tsai HC, Han MH (2016) Sphingosine-1-phosphate (S1P) and S1P signaling pathway: therapeutic targets in autoimmunity and inflammation. Drugs 76:1067–1079
Garris CS, Wu L, Acharya S, Arac A, Blaho VA, Huang Y, Moon BS, Axtell RC, Ho PP, Steinberg GK, Lewis DB, Sobel RA, Han DK, Steinman L, Snyder MP, Hla T, Han MH (2013) Defective sphingosine 1-phosphate receptor 1 (S1P1) phosphorylation exacerbates TH17-mediated autoimmune neuroinflammation. Nat Immunol 14:1166–1172
Tintore M, Vidal-Jordana A, Sastre-Garriga J (2019) Treatment of multiple sclerosis - success from bench to bedside. Nat Rev Neurol 15:53–58
La Mantia L, Tramacere I, Firwana B, Pacchetti I, Palumbo R, Filippini G (2016) Fingolimod for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 4:CD009371
Van Doorn R, Van Horssen J, Verzijl D et al (2010) Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions. Glia 58:1465–1476
Noda H, Takeuchi H, Mizuno T, Suzumura A (2013) Fingolimod phosphate promotes the neuroprotective effects of microglia. J Neuroimmunol 256:13–18
Hunter SF, Bowen JD, Reder AT (2016) The direct effects of fingolimod in the central nervous system: implications for relapsing multiple sclerosis. CNS Drugs 30:135–147
Jin H, Yang H, Liu H, Zhang Y, Zhang X, Rosenberg AJ, Liu Y, Lapi SE, Tu Z (2017) A promising carbon-11-labeled sphingosine-1-phosphate receptor 1-specific PET tracer for imaging vascular injury. J Nucl Cardiol 24:558–570
Liu H, Jin H, Yue X et al (2017) PET study of sphingosine-1-phosphate receptor 1 expression in response to vascular inflammation in a rat model of carotid injury. Mol Imaging 16:1536012116689770
Liu H, Jin H, Yue X, Luo Z, Liu C, Rosenberg AJ, Tu Z (2016) PET imaging study of S1PR1 expression in a rat model of multiple sclerosis. Mol Imaging Biol 18:724–732
Rosenberg AJ, Liu H, Jin H, Yue X, Riley S, Brown SJ, Tu Z (2016) Design, synthesis, and in vitro and in vivo evaluation of an 18F-labeled sphingosine 1-phosphate receptor 1 (S1P1) PET tracer. J Med Chem 59:6201–6220
Luo Z, Rosenberg AJ, Liu H, Han J, Tu Z (2018) Syntheses and in vitro evaluation of new S1PR1 compounds and initial evaluation of a lead F-18 radiotracer in rodents. Eur J Med Chem 150:796–808
Luo Z, Han J, Liu H, Rosenberg AJ, Chen DL, Gropler RJ, Perlmutter JS, Tu Z (2018) Syntheses and in vitro biological evaluation of S1PR1 ligands and PET studies of four F-18 labeled radiotracers in the brain of nonhuman primates. Org Biomol Chem 16:9171–9184
Liptrot M, Adams KH, Martiny L, Pinborg LH, Lonsdale MN, Olsen NV, Holm S, Svarer C, Knudsen GM (2004) Cluster analysis in kinetic modelling of the brain: a noninvasive alternative to arterial sampling. Neuroimage 21:483–493
Zhou Y, Resnick SM, Ye W, Fan H, Holt DP, Klunk WE, Mathis CA, Dannals R, Wong DF (2007) Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer’s disease. Neuroimage 36:298–312
Zhou Y, Ye W, Brasic JR, Crabb AH, Hilton J, Wong DF (2009) A consistent and efficient graphical analysis method to improve the quantification of reversible tracer binding in radioligand receptor dynamic PET studies. Neuroimage 44:661–670
McCluskey SP, Plisson C, Rabiner EA, Howes O (2020) Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development. Eur J Nucl Med Mol Imaging 47:451–489
Pike VW (2016) Considerations in the development of reversibly binding PET radioligands for brain imaging. Curr Med Chem 23:1818–1869
Rankovic Z (2015) CNS drug design: balancing physicochemical properties for optimal brain exposure. J Med Chem 58:2584–2608
Li J, Zhang X, Jin H, Fan J, Flores H, Perlmutter JS, Tu Z (2015) Synthesis of fluorine-containing phosphodiesterase 10A (PDE10A) inhibitors and the in vivo evaluation of F-18 labeled PDE10A PET tracers in rodent and nonhuman primate. J Med Chem 58:8584–8600
Zoghbi SS, Shetty HU, Ichise M, Fujita M, Imaizumi M, Liow JS, Shah J, Musachio JL, Pike VW, Innis RB (2006) PET imaging of the dopamine transporter with 18F-FECNT: a polar radiometabolite confounds brain radioligand measurements. J Nucl Med 47:520–527
Guerrero M, Urbano M, Roberts E (2016) Sphingosine 1-phosphate receptor 1 agonists: a patent review (2013-2015). Expert Opin Ther Pat 26:455–470
Roberts E, Guerrero M, Urbano M, Rosen H (2013) Sphingosine 1-phosphate receptor agonists: a patent review (2010-2012). Expert Opin Ther Pat 23:817–841
Park SJ, Im DS (2017) Sphingosine 1-phosphate receptor modulators and drug discovery. Biomol Ther (Seoul) 25:80–90
Sucksdorff M, Rissanen E, Tuisku J, Nuutinen S, Paavilainen T, Rokka J, Rinne J, Airas L (2017) Evaluation of the effect of fingolimod treatment on microglial activation using serial PET imaging in multiple sclerosis. J Nucl Med 58:1646–1651
Owen DR, Yeo AJ, Gunn RN, Song K, Wadsworth G, Lewis A, Rhodes C, Pulford DJ, Bennacef I, Parker CA, StJean PL, Cardon LR, Mooser VE, Matthews PM, Rabiner EA, Rubio JP (2012) An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab 32:1–5
Acknowledgments
The 18F-fluorine used this study was provided by Washington University Cyclotron Facility. The animal studies were conducted in Washington University Preclinical Imaging Facility. The authors would like to thank the staff of the Cyclotron Facility and the Preclinical Imaging Facility. The authors also thank Lynne Jones for manuscript editing.
Funding
This work was supported by the USA National Institutes of Health (NS075527, NS103957, NS103988, and EB025815).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
ESM 1
(DOCX 418 kb)
Rights and permissions
About this article
Cite this article
Liu, H., Luo, Z., Gu, J. et al. In vivo Characterization of Four 18F-Labeled S1PR1 Tracers for Neuroinflammation. Mol Imaging Biol 22, 1362–1369 (2020). https://doi.org/10.1007/s11307-020-01514-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11307-020-01514-8